Will Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?
Estimates vary wildly about how much Biogen’s new Alzheimer’s drug will cost Medicare — and the total will have real consequences. More
Estimates vary wildly about how much Biogen’s new Alzheimer’s drug will cost Medicare — and the total will have real consequences. More
A new questionnaire funded by AbbVie conflates antidepressant side effects with bipolar disorder and isn't actually a "screening" tool. More
This Viewpoint explains the national Vital Signs initiative—developed by the National Academy of Medicine to track improvements in health, health care costs, engagement of the public in its health, and health care and quality. More
Doctors told STAT it will be critical — and exceedingly difficult — to determine whether Aduhelm's effects are waning with time. More
Last week we covered CBD and mental health, finding that data to back up health claims are scarce and that consumer CBD products are often sketchy. In this week’s episode on CBD and other health ailments, we find that many of the same caveats apply. More
The Alzheimer’s treatment will cost $56,000 per patient, and millions may use it. The result: “crazy numbers” for Medicare. More
After choosing to disclose past trauma or sexual abuse on screening forms, patients are often left wondering if it was a mistake to disclose. More
Value-based payment models may exacerbate racial health disparities. To change this, we need to make equity a part of value -- and reward hospitals for advancing equity. More
State budgets are already being squeezed by rising health care costs, leaving less for public health and social spending. How will the cost of new Alzheimer's drug Aduhelm impact Medicaid costs and state budgets? More
The FDA's approval of a new Alzheimer's treatment has significant implications for future drug trials, health system costs, patient safety, and conflicts of interest. More
A study also found the rate of death caused by falls in older adults more than doubled during the same time period. But more research is needed to understand why. More
Statins have not been proven to increase survival in the combined primary and secondary prevention population of people over 70. More
Medical subscriptions, a $199 million CEO payday and the race to fix primary care in the U.S. One Medical is betting big that a subscription model can fix primary care. More
Older adults often take more medications than they need, or than is safe. Increasingly, geriatric experts and their patients are exploring the benefits of “deprescribing.” More
This cohort study examines the frequency of use and persistent use of benzodiazepines among patients undergoing major and minor surgical procedures. More
Overuse is ubiquitous across medical specialties, and obstetrics and gynecology are no exceptions. Two recent studies shine a light on the problem of overuse in women's health. More
“Overuse is ubiquitous,” said Dr. Vikas Saini, president of the Lown Institute. “Nearly every hospital is doing at least some things that patients don’t really need.”
“There is improvement,” he added, “but it is very slow and it is very uneven.”
Saini, of the Lown Institute, said he hopes more attention on overuse will push hospitals to do better. “We’re trying to create new norms for what it means to be a good hospital,” he said.
The US health system pushes treatment over prevention. This approach has many flaws, one of the most unfortunate and costly being overdiagnosis and overtreatment. More
According to Dr. Vikas Saini, president of the Lown Institute, a think tank that analyzes low-value health care, sleep studies fall into a gray zone.
General anesthesia is necessary for some medical procedures, but can put children and older adults at risk of harm. In this guest blog, a medical student shares what they're learning about avoiding anesthesia overuse. More